二线用药EGFR—TKIs治疗非选择型NSCLC疗效的Meta分析(4)
[11]Wu YL，Zhou C，Hu CP，et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6)：an open-label，randomised phase 3 trial[J].Lancet Oncology，2014，15(2)：213-222.[12]Rosell R，Carcereny E，Gervais R，et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC)：a multicentre ......
您现在查看是摘要页，全文长 3194 字符。